SK78196A3 - Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them - Google Patents
Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them Download PDFInfo
- Publication number
- SK78196A3 SK78196A3 SK781-96A SK78196A SK78196A3 SK 78196 A3 SK78196 A3 SK 78196A3 SK 78196 A SK78196 A SK 78196A SK 78196 A3 SK78196 A3 SK 78196A3
- Authority
- SK
- Slovakia
- Prior art keywords
- groups
- group
- rapamycin
- demethoxy
- formula
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 49
- 229960002930 sirolimus Drugs 0.000 title claims description 71
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims description 40
- 238000002360 preparation method Methods 0.000 title claims 5
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 88
- -1 hydroxyarylalkyl Chemical group 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 11
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims description 7
- 125000005027 hydroxyaryl group Chemical group 0.000 claims description 7
- 230000036457 multidrug resistance Effects 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 125000004001 thioalkyl group Chemical group 0.000 claims description 7
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000005016 hydroxyalkynyl group Chemical group 0.000 claims description 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 125000004945 acylaminoalkyl group Chemical group 0.000 claims description 4
- 125000005103 alkyl silyl group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 3
- 125000004803 chlorobenzyl group Chemical group 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000005042 acyloxymethyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 125000002034 haloarylalkyl group Chemical group 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 8
- 229960003444 immunosuppressant agent Drugs 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000010934 O-alkylation reaction Methods 0.000 description 3
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036941 Cyclosporins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical class CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 125000005182 hydroxyalkylcarbonyl group Chemical group 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- VYKNVAHOUNIVTQ-UHFFFAOYSA-N 1,2,2,3,3-pentamethylpiperidine Chemical class CN1CCCC(C)(C)C1(C)C VYKNVAHOUNIVTQ-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 101710155214 Macrophage infectivity potentiator Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 101710114693 Outer membrane protein MIP Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001675 anti-mdr Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- PVYPHUYXKVVURH-UHFFFAOYSA-N boron;2-methylpropan-2-amine Chemical compound [B].CC(C)(C)N PVYPHUYXKVVURH-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
- 229950010231 brequinar Drugs 0.000 description 1
- NEEDEQSZOUAJMU-UHFFFAOYSA-N but-2-yn-1-ol Chemical compound CC#CCO NEEDEQSZOUAJMU-UHFFFAOYSA-N 0.000 description 1
- DLDJFQGPPSQZKI-UHFFFAOYSA-N but-2-yne-1,4-diol Chemical compound OCC#CCO DLDJFQGPPSQZKI-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 108010019249 cyclosporin G Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical group CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000002620 ureteric effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939325800A GB9325800D0 (en) | 1993-12-17 | 1993-12-17 | Organic compounds |
GB939325802A GB9325802D0 (en) | 1993-12-17 | 1993-12-17 | Organic compounds |
GB9407138A GB9407138D0 (en) | 1994-04-11 | 1994-04-11 | Organic compounds |
GB9421982A GB9421982D0 (en) | 1994-11-01 | 1994-11-01 | Organic compounds |
PCT/EP1994/004191 WO1995016691A1 (fr) | 1993-12-17 | 1994-12-16 | Derives de rapamycine utilises comme immonosuppresseurs |
Publications (1)
Publication Number | Publication Date |
---|---|
SK78196A3 true SK78196A3 (en) | 1997-02-05 |
Family
ID=27451097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK781-96A SK78196A3 (en) | 1993-12-17 | 1994-12-16 | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
Country Status (21)
Country | Link |
---|---|
US (1) | US5912253A (fr) |
EP (1) | EP0734389B1 (fr) |
JP (1) | JP3745772B2 (fr) |
CN (1) | CN1046944C (fr) |
AT (1) | ATE191218T1 (fr) |
AU (1) | AU687491B2 (fr) |
BR (1) | BR9408323A (fr) |
CZ (1) | CZ284650B6 (fr) |
DE (1) | DE69423781T2 (fr) |
DK (1) | DK0734389T3 (fr) |
ES (1) | ES2146741T3 (fr) |
FI (1) | FI962487A0 (fr) |
GR (1) | GR3033545T3 (fr) |
HU (1) | HUT74686A (fr) |
NO (1) | NO962540L (fr) |
NZ (1) | NZ277498A (fr) |
PL (1) | PL314238A1 (fr) |
PT (1) | PT734389E (fr) |
SG (1) | SG64372A1 (fr) |
SK (1) | SK78196A3 (fr) |
WO (1) | WO1995016691A1 (fr) |
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US7279561B1 (en) * | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
AU686629B2 (en) | 1993-04-23 | 1998-02-12 | Wyeth | Rapamycin Conjugates and Antibodies |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
RU2158267C2 (ru) | 1995-06-09 | 2000-10-27 | Новартис Аг | Производные рапамицина и фармацевтическая композиция на их основе |
GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
EP1158985B1 (fr) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
AU769315B2 (en) | 1999-08-24 | 2004-01-22 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
WO2001014387A1 (fr) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | Analogues d'epirapamycine-28 |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US7300662B2 (en) * | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
MXPA03002871A (es) | 2000-09-29 | 2004-12-06 | Johnson & Johnson | Dispositivos medicos recubiertos. |
US20040241211A9 (en) * | 2000-11-06 | 2004-12-02 | Fischell Robert E. | Devices and methods for reducing scar tissue formation |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US6534693B2 (en) | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
US6821731B2 (en) | 2000-11-28 | 2004-11-23 | Wyeth | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2011226833B9 (en) * | 2001-02-19 | 2014-07-03 | Novartis Ag | Cancer treatment |
AU2005201004A1 (en) * | 2001-02-19 | 2005-03-24 | Novartis Ag | Cancer treatment |
ES2728739T3 (es) | 2001-02-19 | 2019-10-28 | Novartis Pharma Ag | Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada |
AU2016206379B2 (en) * | 2001-02-19 | 2017-09-14 | Novartis Ag | Cancer Treatment |
US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
EP1458405A1 (fr) * | 2001-11-21 | 2004-09-22 | Sucampo AG | Utilisation de fk506 et d'analogues de celui-ci pour traiter des maladies allergiques |
PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
US20040072796A1 (en) * | 2002-04-18 | 2004-04-15 | Embury Stephen H. | Method and composition for preventing pain in sickle cell patients |
US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
CA2483594C (fr) | 2002-05-16 | 2011-02-15 | Novartis Ag | Utilisation d'agents de liaison du recepteur edg dans le cancer |
JP4265888B2 (ja) * | 2002-06-12 | 2009-05-20 | 株式会社リコー | 画像形成装置 |
ES2296063T3 (es) | 2002-07-16 | 2008-04-16 | Biotica Technology Limited | Produccion de poliquetidos y otros productos naturales. |
US20060046979A1 (en) | 2002-09-24 | 2006-03-02 | Foster Carolyn A | Organic compounds |
WO2004060283A2 (fr) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Composes a base de rapamycine nitrosee et nitrosylee, compositions et procedes d'utilisation |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
JP2007511203A (ja) | 2003-05-20 | 2007-05-10 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害活性を有するジアリール尿素 |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
CN102144961A (zh) * | 2003-09-18 | 2011-08-10 | 参天制药株式会社 | 经巩膜递送 |
US7220755B2 (en) * | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US20050142161A1 (en) * | 2003-12-30 | 2005-06-30 | Freeman Lynetta J. | Collagen matrix for soft tissue augmentation |
WO2006115509A2 (fr) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
US7901451B2 (en) * | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
US8637070B2 (en) * | 2005-02-09 | 2014-01-28 | Santen Pharmaceutical Co., Ltd. | Rapamycin formulations and methods of their use |
GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
EP1896018A2 (fr) | 2005-03-11 | 2008-03-12 | Biotica Technology Limited | Utilisations medicales de 39-demethoxy-rapamicyne et ses analogues |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
EP1909794A2 (fr) | 2005-07-20 | 2008-04-16 | Novartis AG | Combinaison de composes organiques |
RS54088B1 (en) | 2005-07-25 | 2015-10-30 | Emergent Products Development Seattle Llc | B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES |
ES2611307T3 (es) | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
CA2635797C (fr) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Formulations stables et leurs procedes de preparation et d'utilisation |
US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
US20080097591A1 (en) * | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
US8067055B2 (en) * | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
US20080103584A1 (en) * | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
AU2007339762B2 (en) | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
WO2008082984A2 (fr) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Réactif de lyse non dénaturante destiné à être utilisé en immunoessai de capture en solution |
ES2393135T3 (es) | 2006-12-29 | 2012-12-18 | Abbott Laboratories | Ensayo mejorado para fármacos inmunosupresores |
US7914999B2 (en) | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
ES2405364T3 (es) | 2006-12-29 | 2013-05-30 | Abbott Laboratories | Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
KR100930167B1 (ko) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | 초광각 광학계 |
WO2009089549A1 (fr) | 2008-01-11 | 2009-07-16 | Massachusetts Eye & Ear Infirmary | Animaux transgéniques de caspase dimérisable d'arrêt conditionnel |
US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
NZ588671A (en) | 2008-04-11 | 2012-11-30 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US20110152380A1 (en) | 2008-06-20 | 2011-06-23 | Kovarik John M | Paediatric Compositions For Treating Multiple Sclerosis |
CN102292078A (zh) | 2008-11-11 | 2011-12-21 | 得克萨斯大学体系董事会 | 哺乳动物雷帕霉素靶蛋白的抑制 |
EP2393827B1 (fr) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Nouveaux promédicaments à base d'inhibiteurs cyp17 stéroïdiens/anti-androgènes |
CN101924315B (zh) * | 2009-06-16 | 2014-09-03 | 德昌电机(深圳)有限公司 | 换向器及其制造方法 |
JP2013501057A (ja) | 2009-08-03 | 2013-01-10 | ユニバーシティー・オブ・マイアミ | 制御性t細胞のinvivoにおける増殖 |
IN2012DN02753A (fr) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
WO2015161139A1 (fr) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Préparation orale de rapamycine et utilisation pour une stomatite |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
EP2558092B1 (fr) | 2010-04-13 | 2018-06-27 | Novartis AG | Combinaison comprenant un inhibiteur de kinase dépendante de cycline 4 ou de kinase dependante de cycline 6 (cdk4/6) et de l'everolimus pour traiter le cancer |
SG184311A1 (en) | 2010-04-16 | 2012-11-29 | Novartis Ag | Combination of organic compounds |
EP2563391B1 (fr) | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR |
KR102024948B1 (ko) | 2011-02-18 | 2019-11-04 | 노파르티스 파르마 아게 | mTOR/JAK 저해제 병용 요법 |
WO2012149014A1 (fr) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer |
WO2012148846A1 (fr) | 2011-04-25 | 2012-11-01 | Novartis Ag | Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor |
EP2589383A1 (fr) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Analogue de rapamycine spécifique au sous-type de FKBP à utiliser dans le traitement des maladies |
RU2014124184A (ru) | 2011-11-15 | 2015-12-27 | Новартис Аг | Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5 |
GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
EP3939572B1 (fr) | 2012-04-12 | 2024-03-27 | Yale University | Véhicules pour l'administration contrôlée d'agents pharmaceutiques différents |
WO2013192367A1 (fr) | 2012-06-22 | 2013-12-27 | Novartis Ag | Traitement d'une tumeur neuroendocrine |
EP2869818A1 (fr) | 2012-07-06 | 2015-05-13 | Novartis AG | Combinaison d'un inhibiteur de phosphoinositide 3-kinase et d'un inhibiteur de l'interaction il-8/cxcr |
WO2014059295A1 (fr) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire |
EP2919759A4 (fr) | 2012-11-14 | 2016-07-20 | Ohio State Innovation Foundation | Matières et procédés utiles pour le traitement du glioblastome |
EP2934575A2 (fr) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | Anticorps spécifiques de b7-h4, compositions et utilisations de ceux-ci |
WO2014110258A1 (fr) | 2013-01-09 | 2014-07-17 | Podack Eckhard R | Compositions et procédés pour la régulation de lymphocytes t régulateurs à l'aide d'une protéine d'une fusion tl1a-ig |
WO2014160328A1 (fr) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux |
KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
AU2014265142A1 (en) | 2013-05-17 | 2015-12-24 | Medimmune, Llc | Receptors for B7-H4 |
WO2014200659A1 (fr) | 2013-06-11 | 2014-12-18 | Clontech Laboratories, Inc. | Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation |
BR112016002970A2 (pt) | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
EP3068435A1 (fr) | 2013-11-13 | 2016-09-21 | Novartis AG | Inhibiteurs de mtor ameliorant la reponse immunitaire |
RU2714902C2 (ru) | 2013-12-19 | 2020-02-20 | Новартис Аг | Химерные рецепторы антигена против мезотелина человека и их применение |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CA3206208A1 (fr) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Preparations orales de nanoparticules de rapamycine, et utilisation |
KR20160110963A (ko) | 2014-02-11 | 2016-09-23 | 노파르티스 아게 | 암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물 |
EP3593812A3 (fr) | 2014-03-15 | 2020-05-27 | Novartis AG | Traitement du cancer à l'aide d'un récepteur d'antigène chimérique |
WO2015142661A1 (fr) | 2014-03-15 | 2015-09-24 | Novartis Ag | Récepteur d'antigène chimèrique régulable |
CA2943609A1 (fr) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Conjugues de medicaments actives metaboliquement pour vaincre la resistance dans une therapie du cancer |
KR20240042250A (ko) | 2014-04-07 | 2024-04-01 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
US10258639B2 (en) | 2014-05-06 | 2019-04-16 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy |
CA2950589A1 (fr) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Procedes et compositions pour une immunomodulation |
CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
WO2016025880A1 (fr) | 2014-08-14 | 2016-02-18 | Novartis Ag | Traitement du cancer à l'aide du récepteur d'antigène chimérique gfr alpha-4 |
SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
EP3193902A4 (fr) | 2014-09-11 | 2018-03-28 | The Regents of The University of California | Inhibiteurs de mtorc1 |
US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
JP6815992B2 (ja) | 2014-10-08 | 2021-01-20 | ノバルティス アーゲー | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 |
WO2016068208A1 (fr) | 2014-10-28 | 2016-05-06 | 国立研究開発法人国立成育医療研究センター | Medicament pour ameliorer l'etat de grossesse, et son utilisation |
WO2016066608A1 (fr) | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de la sénescence des cellules pulmonaires et le vieillissement périphérique |
FR3033499A1 (fr) | 2015-03-11 | 2016-09-16 | Centre Leon-Berard | Composition pour le traitement des tumeurs neuroendocrines pancreatiques |
EP3280795B1 (fr) | 2015-04-07 | 2021-03-24 | Novartis AG | Combinaison de traitement à l'aide du récepteur antigénique chimérique et de derivés de l'amino pyrimidine |
US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
EP3286211A1 (fr) | 2015-04-23 | 2018-02-28 | Novartis AG | Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase |
CN106188093B (zh) * | 2015-05-08 | 2018-06-12 | 上海医药工业研究院 | 一种雷帕霉素结构类似物及其制备方法 |
AU2016263176A1 (en) | 2015-05-20 | 2017-12-07 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
CA2997442C (fr) | 2015-09-04 | 2021-01-26 | Yale University | Nanocompositions d'acide biliaire polymere visant le pancreas et le colon |
AU2016352806A1 (en) | 2015-11-11 | 2018-05-10 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and uses thereof |
US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
CN116077439A (zh) | 2016-04-29 | 2023-05-09 | 西奈山伊坎医学院 | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 |
CA3031542A1 (fr) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Lymphocytes car-t cd229 et leurs procedes d'utilisation |
US11390675B2 (en) | 2016-09-21 | 2022-07-19 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
CN117866991A (zh) | 2016-10-07 | 2024-04-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
WO2018096402A1 (fr) | 2016-11-23 | 2018-05-31 | Novartis Ag | Méthodes d'amélioration de la réponse immunitaire à l'évérolimus, au dactolisib ou aux deux |
EP3548894B1 (fr) | 2016-12-02 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions permettant de diagnostiquer le carcinome cellulaire rénal |
HUE056777T2 (hu) | 2016-12-22 | 2022-03-28 | Amgen Inc | Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére |
JP2020507632A (ja) | 2017-02-10 | 2020-03-12 | マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. | ラパマイシン類似体 |
EP3615055A1 (fr) | 2017-04-28 | 2020-03-04 | Novartis AG | Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase |
ES2871499T3 (es) | 2017-05-15 | 2021-10-29 | Bard Inc C R | Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
JP7150823B2 (ja) | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | KRas G12Cの阻害剤及びそれを使用する方法 |
WO2019157516A1 (fr) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Polythérapies |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
CR20200578A (es) | 2018-05-01 | 2021-02-22 | Revolution Medicines Inc | Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor |
CN112368289B (zh) | 2018-05-01 | 2024-02-20 | 锐新医药公司 | 作为mtor抑制剂的c26-连接的雷帕霉素类似物 |
WO2019213282A1 (fr) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarqueurs pour évaluer des cellules car-t pour prédire un résultat clinique |
JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US20210115378A1 (en) | 2018-05-09 | 2021-04-22 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
EP3790592A1 (fr) | 2018-05-09 | 2021-03-17 | Yale University | Particules pour la libération spatio-temporelle d'agents |
EP3790886A1 (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
WO2019232419A1 (fr) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
CA3099799A1 (fr) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
WO2019241789A1 (fr) * | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Analogues de la rapamycine et leurs utilisations |
CN112533599A (zh) | 2018-08-10 | 2021-03-19 | 山口晃史 | 与母体和胎儿的关系中的体液免疫相关的疾病的治疗药 |
EP3880266A1 (fr) | 2018-11-14 | 2021-09-22 | Lutonix, Inc. | Dispositif médical avec revêtement à élution de médicament sur un dispositif à surface modifiée |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
CA3117222A1 (fr) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
JPWO2020129348A1 (ja) | 2018-12-18 | 2021-11-04 | 晃史 山口 | 不妊・不育症または妊娠状態を改善するための薬剤 |
EP3897852A1 (fr) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Inhibiteurs de kif18a |
EP3897855B1 (fr) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Inhibiteurs de kif18a |
EP3898616A1 (fr) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
WO2020132653A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
WO2020154447A1 (fr) * | 2019-01-22 | 2020-07-30 | Aeovian Pharmaceuticals, Inc. | Modulateurs de mtorc et leurs utilisations |
CA3130083A1 (fr) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Composes heterocyclyle bicycliques et leurs utilisations |
MX2021010319A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos biciclicos de heteroarilo y usos de estos. |
WO2020209828A1 (fr) | 2019-04-08 | 2020-10-15 | Bard Peripheral Vascular, Inc. | Dispositif médical portant un revêtement d'élution de médicament sur une surface modifiée de dispositif |
EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
WO2021001743A1 (fr) | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Inhibiteurs de traduction et leurs utilisations |
WO2021026098A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
CA3147272A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
AU2020325115A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
WO2021026101A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
WO2021055728A1 (fr) | 2019-09-18 | 2021-03-25 | Merck Sharp & Dohme Corp. | Inhibiteurs à petites molécules de mutant de kras g12c |
CA3155857A1 (fr) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Derives de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer |
EP4051678A1 (fr) | 2019-10-28 | 2022-09-07 | Merck Sharp & Dohme Corp. | Inhibiteurs à petites molécules de mutant de kras g12c |
EP4051266A1 (fr) | 2019-10-31 | 2022-09-07 | Taiho Pharmaceutical Co., Ltd. | Dérivés de 4-aminobut-2-enamide et sels de ces derniers |
EP4055028A1 (fr) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
AU2020381492A1 (en) | 2019-11-14 | 2022-05-26 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
US20230192682A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021108683A1 (fr) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
WO2021106231A1 (fr) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | Composé ayant une activité inhibitrice contre la mutation kras g12d |
TW202134234A (zh) * | 2019-12-05 | 2021-09-16 | 美商奈維特製藥公司 | 雷帕黴素類似物及其用途 |
JP2023509701A (ja) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ,インコーポレイテッド | Shp2阻害剤投薬およびがんを処置する方法 |
JP2023530778A (ja) | 2020-03-27 | 2023-07-19 | エオビアン ファーマシューティカルズ, インコーポレイテッド | Mtorc1モジュレーターおよびその使用 |
EP4139299A1 (fr) | 2020-04-24 | 2023-03-01 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs de protéine kras g12d |
WO2021215545A1 (fr) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Polythérapie anticancéreuse avec un inhibiteur de n-(1-acryloyl-azétidin-3-yl)-2-((1h-indazol-3-yl) amino) méthyl)-1 h-imidazole-5-carboxamide de kras-g12c |
CN116600789A (zh) | 2020-06-19 | 2023-08-15 | 耶鲁大学 | 用于诱导耐受性的聚合胆汁酸酯纳米颗粒 |
KR20230031926A (ko) | 2020-07-15 | 2023-03-07 | 다이호야쿠힌고교 가부시키가이샤 | 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합 |
CN116322677A (zh) * | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
JP2024501280A (ja) | 2020-12-22 | 2024-01-11 | キル・レガー・セラピューティクス・インコーポレーテッド | Sos1阻害剤およびその使用 |
CN117355298A (zh) | 2021-03-19 | 2024-01-05 | 生物治疗探索股份有限公司 | 用于调节训练免疫的化合物及其使用方法 |
WO2022235870A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras pour le traitement du cancer |
WO2022235864A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras |
EP4334324A1 (fr) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
CN117769554A (zh) | 2021-05-28 | 2024-03-26 | 大鹏药品工业株式会社 | Kras突变蛋白的小分子抑制剂 |
CA3223081A1 (fr) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions et methodes associees a des cellules comprenant des particules adherees |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
WO2024081916A1 (fr) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2881886B2 (ja) * | 1989-12-30 | 1999-04-12 | ソニー株式会社 | 映像信号符号化方法及びその装置 |
US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
CA2175215C (fr) * | 1993-11-19 | 2008-06-03 | Yat Sun Or | Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs |
US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
-
1994
- 1994-12-16 CN CN94194522A patent/CN1046944C/zh not_active Expired - Fee Related
- 1994-12-16 SG SG1996009086A patent/SG64372A1/en unknown
- 1994-12-16 PL PL94314238A patent/PL314238A1/xx unknown
- 1994-12-16 NZ NZ277498A patent/NZ277498A/en unknown
- 1994-12-16 DE DE69423781T patent/DE69423781T2/de not_active Expired - Lifetime
- 1994-12-16 PT PT95903810T patent/PT734389E/pt unknown
- 1994-12-16 CZ CZ961757A patent/CZ284650B6/cs not_active IP Right Cessation
- 1994-12-16 SK SK781-96A patent/SK78196A3/sk unknown
- 1994-12-16 AU AU12739/95A patent/AU687491B2/en not_active Ceased
- 1994-12-16 EP EP95903810A patent/EP0734389B1/fr not_active Expired - Lifetime
- 1994-12-16 ES ES95903810T patent/ES2146741T3/es not_active Expired - Lifetime
- 1994-12-16 HU HU9601643A patent/HUT74686A/hu unknown
- 1994-12-16 BR BR9408323A patent/BR9408323A/pt not_active Application Discontinuation
- 1994-12-16 DK DK95903810T patent/DK0734389T3/da active
- 1994-12-16 JP JP51654495A patent/JP3745772B2/ja not_active Expired - Fee Related
- 1994-12-16 US US08/663,169 patent/US5912253A/en not_active Expired - Fee Related
- 1994-12-16 WO PCT/EP1994/004191 patent/WO1995016691A1/fr active IP Right Grant
- 1994-12-16 AT AT95903810T patent/ATE191218T1/de not_active IP Right Cessation
-
1996
- 1996-06-14 FI FI962487A patent/FI962487A0/fi unknown
- 1996-06-14 NO NO962540A patent/NO962540L/no unknown
-
2000
- 2000-05-31 GR GR20000401237T patent/GR3033545T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR9408323A (pt) | 1997-08-19 |
EP0734389B1 (fr) | 2000-03-29 |
NO962540D0 (no) | 1996-06-14 |
AU687491B2 (en) | 1998-02-26 |
DK0734389T3 (da) | 2000-08-21 |
EP0734389A1 (fr) | 1996-10-02 |
DE69423781D1 (de) | 2000-05-04 |
CN1046944C (zh) | 1999-12-01 |
DE69423781T2 (de) | 2000-08-10 |
PL314238A1 (en) | 1996-09-02 |
HU9601643D0 (en) | 1996-08-28 |
FI962487A (fi) | 1996-06-14 |
NZ277498A (en) | 1998-03-25 |
HUT74686A (en) | 1997-01-28 |
AU1273995A (en) | 1995-07-03 |
WO1995016691A1 (fr) | 1995-06-22 |
FI962487A0 (fi) | 1996-06-14 |
PT734389E (pt) | 2000-09-29 |
ATE191218T1 (de) | 2000-04-15 |
SG64372A1 (en) | 1999-04-27 |
ES2146741T3 (es) | 2000-08-16 |
CN1137797A (zh) | 1996-12-11 |
CZ175796A3 (en) | 1996-09-11 |
CZ284650B6 (cs) | 1999-01-13 |
GR3033545T3 (en) | 2000-09-29 |
US5912253A (en) | 1999-06-15 |
NO962540L (no) | 1996-06-14 |
JP3745772B2 (ja) | 2006-02-15 |
JPH09506604A (ja) | 1997-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5912253A (en) | Rapamycin derivatives | |
EP0663916B1 (fr) | Derive o-alkyle de la rapamycine et son utilisation, en particulier comme immunosuppresseur | |
RU2158267C2 (ru) | Производные рапамицина и фармацевтическая композиция на их основе | |
CA2174731C (fr) | Derives de rapamycine utilises comme immonosuppresseurs | |
MXPA97009555A (en) | Derivatives of rapamic |